Phreesia (PHR) Stock Price, News & Analysis

Company Overview

Phreesia, Inc. (NYSE: PHR) is a leading provider of patient intake and engagement solutions for healthcare organizations, offering a comprehensive software-as-a-service platform designed to automate front-office administrative tasks. Founded in 2005 and headquartered in Burlington, Massachusetts, Phreesia has developed a digital suite that streamlines appointment scheduling, patient check-in, insurance verification, consent collection and payment processing. The company’s cloud-based system integrates with electronic health record (EHR) systems to ensure a seamless flow of patient data and reduce manual paperwork.

Phreesia’s core offerings include self-service kiosks, tablet and web-based check-in applications, mobile intake options and a range of specialized modules such as prescreening questionnaires, immunization tracking and telehealth scheduling. By leveraging automation and real-time data capture, the platform helps providers enhance operational efficiency, improve patient satisfaction and accelerate revenue cycle workflows. Phreesia also offers analytics tools that enable organizations to monitor key performance indicators and identify areas for clinical and financial improvement.

Serving more than 11,000 provider organizations across the United States and Canada, Phreesia’s customer base spans large health systems, community hospitals, physician practices and specialty clinics. The company’s solutions support millions of patient visits each month, accommodating a diverse set of care settings and patient populations. Through strategic partnerships with leading EHR vendors and payers, Phreesia continues to expand its geographic reach and enhance interoperability within the broader healthcare ecosystem.

Phreesia is led by co-founder and Chief Executive Officer Chahine Azar, who has guided the company from its inception to a publicly traded enterprise. Under Azar’s leadership, the executive team has prioritized innovation, regulatory compliance and user-centered design. With a focus on ongoing product development, Phreesia invests in emerging technologies such as artificial intelligence and machine learning to further refine its intake platform and support the evolving needs of modern healthcare delivery.

Key Stats

• Today's Range: $25.92 to $27.30
• 50-Day Range: $23.33 to $29.09
• 52-Week Range: $17.07 to $30.53
• Volume: 659,101 shs
• Average Volume: 451,595 shs
• Market Capitalization: $1.55 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.27
• Consensus Rating: Buy

Phreesia Stock Analysis - MarketRank™

Phreesia scored higher than 69% of companies evaluated by MarketBeat, and ranked 314th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Phreesia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Phreesia has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Phreesia are expected to grow in the coming year, from ($1.10) to ($0.38) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Phreesia is -35.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Phreesia is -35.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Phreesia has a P/B Ratio of 5.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.35% of the float of Phreesia has been sold short.

Short Interest Ratio / Days to Cover

Phreesia has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Phreesia has recently increased by 8.18%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Phreesia does not currently pay a dividend.

Dividend Growth

Phreesia does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.60

Percentage of Shares Shorted

6.35% of the float of Phreesia has been sold short.

Short Interest Ratio / Days to Cover

Phreesia has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Phreesia has recently increased by 8.18%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.36

News Sentiment

Phreesia has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Phreesia this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for PHR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

2 people have added Phreesia to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Phreesia insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,329,816.00 in company stock.

Percentage Held by Insiders

Only 5.50% of the stock of Phreesia is held by insiders.

Percentage Held by Institutions

92.10% of the stock of Phreesia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PHR Stock Analysis - Frequently Asked Questions

How have PHR shares performed this year?

Phreesia's stock was trading at $25.16 at the start of the year. Since then, PHR stock has increased by 3.4% and is now trading at $26.0110.

How were Phreesia's earnings last quarter?

Phreesia, Inc. (NYSE:PHR) posted its quarterly earnings data on Wednesday, May, 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.06. The firm's revenue was up 14.5% on a year-over-year basis.
Read the conference call transcript.

When did Phreesia IPO?

Phreesia (PHR) raised $127 million in an initial public offering on Thursday, July 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.62 per share. J.P. Morgan, Wells Fargo Securities, William Blair, Allen & Company and Piper Jaffray served as the underwriters for the IPO.

Who are Phreesia's major shareholders?

Phreesia's top institutional investors include Riverbridge Partners LLC (0.93%), Moody National Bank Trust Division (0.19%), Diversified Trust Co (0.08%) and Farther Finance Advisors LLC (0.01%). Insiders that own company stock include Chaim Indig, Evan Roberts, David Linetsky, Randy Rasmussen, Michael Weintraub, Allison C Hoffman, Amy Beth Vanduyn, Balaji Gandhi, Michael J Davidoff, Mark Douglas Smith, Janet Gunzburg, Yvonne Hui, Lisa Egbuonu-Davis and Gillian Munson.
View institutional ownership trends.

How do I buy shares of Phreesia?

Shares of PHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Phreesia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Phreesia investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Arista Networks (ANET) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/28/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 9/03/2025
• Fiscal Year End: 1/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Business Services
• Current Symbol: NYSE:PHR
• CIK: 1412408
• Web: www.phreesia.com
• Phone: (888) 654-7473
• Fax: 646-607-1776
• Employees: 2,082
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Phreesia: $32.27
• High Price Target: $35.00
• Low Price Target: $28.00
• Potential Upside/Downside: +24.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.53 million
• Net Margins: -9.83%
• Pretax Margin: -9.15%
• Return on Equity: -16.23%
• Return on Assets: -11.19%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 1.95
• Quick Ratio: 1.95

Sales & Book Value

• Annual Sales: $419.81 million
• Price / Sales: 3.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.56 per share
• Price / Book: 5.70

Miscellaneous

• Outstanding Shares: 59,500,000
• Free Float: 56,231,000
• Market Cap: $1.55 billion
• Optionable: Optionable
• Beta: 0.72